Suchergebnisse - "F0P408N6V4"

PubPharm (403)

1

Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma : a cohort of a multicentre, single-arm, phase 1b/2 study

enthalten in: The Lancet. Haematology | 2024

von Abrisqueta, P. | González-Barca, E. | Panizo, C. | +13

2

MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma : the Nordic Lymphoma Group MCL7 VALERIA trial

enthalten in: Blood advances | 2024

von Jerkeman, M. | Kolstad, A. | Hutchings, M. | +12

3

A prospective, multicenter, observational study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in Japan

enthalten in: Annals of hematology | 2024

von Horigome, Y. | Iino, M. | Harazaki, Y. | +22

4

Progression-Free Survival of Daratumumab Versus Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma : TAURUS Chart Review Study

enthalten in: Clinical lymphoma, myeloma & leukemia | 2024

von Gordan, L. | Tan, C. | Vescio, R. | +12

5

Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma : a multicenter, retrospective, real-world experience with 200 cases outside of controlled clinical trials

enthalten in: Haematologica | 2024

von Gentile, M. | Vigna, E. | Palmieri, S. | +44

6

Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024

von Leypoldt, L. | Tichy, D. | Besemer, B. | +24

7

Tafasitamab and lenalidomide in large B-cell lymphoma : real-world outcomes in a multicenter retrospective study

enthalten in: Blood | 2023

von Qualls, D. | Lambert, N. | Caimi, P. | +21

CommentIn: Blood. 2023 Dec 28;142(26):2232-2234. - PMID 38153771

8

Experience of Daratumumab in Relapsed/Refractory Multiple Myeloma : A Multicenter Study from Türkiye

enthalten in: Turkish journal of haematology : official journal of Turkish Society of Haematology | 2023

von Tekinalp, A. | Gedük, A. | Akdeniz, A. | +19

9

Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma : BMT CTN 1401

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2023

von Chung, D. | Shah, N. | Wu, J. | +36

CommentIn: Clin Cancer Res. 2023 Dec 1;29(23):4703-4705. - PMID 37733765

10

Nine-year follow-up of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma

enthalten in: Blood advances | 2023

von Yamshon, S. | Chen, G. | Gribbin, C. | +9

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[41]